August 15, 2016
CTI Clinical Trial & Consulting Services Announces Lorri Erhardt has joined as Vice President, Clinical Monitoring
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ August 15, 2016]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces Lorri Erhardt has joined as Vice President, Clinical Monitoring. Erhardt has significant experience in global leadership, as well as over thirty years of clinical research experience.
“We are delighted that Lorri has joined CTI’s clinical group,” said Kevin Schwarz, Chief Operating Officer. “Her international leadership experience in drug development will be a huge asset to the growing team at CTI.”
Prior to joining CTI, Erhardt served as Executive Director, Global Head Clinical Site & Document Management at Astellas, where she ensured high quality performance within Site and Document Management department.
Erhardt also held positions at Takeda as Director of Clinical Operations, and at Kendle International, as Director of Global Clinical Development, North America and as Executive Director, Global Head On-Site Monitoring, where she oversaw 800 international associates. She also spent nearly two decades at Pfizer (formerly Searle and Pharmacia), where she began her career in industry as a Clinical Research Associate and worked her way to Senior Director, Head of US Field Operations. While at Searle, she played a key role in the clinical development program for Celebrex®, by coordinating operational aspects for the planning, managing, conducting, and reporting of all clinical trials and the writing of clinical NDA/MAA documents, FDA briefing document and materials used during the successful FDA advisory meeting.
Erhardt has a Bachelor of Science in Medical Technology from Gannon College and has dozens of publications.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com